Compare AbCellera Biologics Inc (ABCL) vs American Homes 4 Rent Class A (AMH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs American Homes 4 Rent Class A — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while American Homes 4 Rent Class A trades at $33.39 (market cap $12.23B). The key difference: American Homes 4 Rent Class A is far larger — about 5.2× AbCellera Biologics Inc's market cap, and American Homes 4 Rent Class A pays a 3.88% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | AMH | |
|---|---|---|
Market Cap | $2.35B | $12.23B |
Sector | Health | Real Estate |
52-Week High | $8.12 | $36.74 |
52-Week Low | $2.78 | $27.38 |
Enterprise Value | $1.99B | $17.32B |
Dividend Yield | — | 3.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
AMH trades at $34.00, down 0.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $35.41. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.35 exceeding expectations of $0.1763. Revenue grew to $1.85 billion in 2025, with a net income margin of 25.27%, while the stock trades at a P/E of 27.45 and P/S of 6.69. A dividend of $0.33 per share is scheduled for payment on June 30, 2026.
AMH presents a positive outlook driven by consistent earnings performance and robust fundamentals, though elevated valuation ratios and high debt levels pose risks. Investor sentiment is supported by bullish analyst ratings and strong occupancy rates in the single-family rental market, but macroeconomic factors and interest rate sensitivity remain key considerations for potential investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About American Homes 4 Rent Class A
American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas
Read more on AMH →
